Filing Flows › Silence Therapeutics (SLN) › Q3 2025
Silence Therapeutics (SLN) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 6, 2025
Silence Therapeutics (SLN) reported revenue of $159K for the third quarter 2025 (Q3 2025), -89% from a year earlier and -29% from the quarter before.
Silence Therapeutics, Q3 2025: revenue $159K (-89% year over year), net loss $21.0M, operating cash flow −$10.9M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $159K | -29% | -89% |
| Operating profit | −$26.2M | — | — |
| Net earnings | −$21.0M | — | — |
| Operating cash flow | −$10.9M | — | — |
What changed
Revenue was $159K in Q3 2025, down 89% year over year and down 29% from the previous quarter.
Gross margin was 59.7%. Operating costs exceeded revenue by $26.2M, an operating margin of -16505.7%. The quarter ended with a net loss of $21.0M, narrower than the previous quarter's $27.4M loss. Non-operating items added $5.3M, -25% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was −$10.9M. Non-cash charges added back $81K of depreciation and $2.5M of share-based compensation. Working capital and other items added $7.5M. Capital expenditures of $3K exceeded it, leaving free cash flow of −$10.9M.
Questions
What was Silence Therapeutics' revenue in the third quarter 2025?
Silence Therapeutics (SLN) reported revenue of $159K for the third quarter 2025 (Q3 2025), -89% from a year earlier and -29% from the quarter before.